WO2002029098A3 - Genetic factors affecting the outcome of viral infections - Google Patents
Genetic factors affecting the outcome of viral infections Download PDFInfo
- Publication number
- WO2002029098A3 WO2002029098A3 PCT/GB2001/004472 GB0104472W WO0229098A3 WO 2002029098 A3 WO2002029098 A3 WO 2002029098A3 GB 0104472 W GB0104472 W GB 0104472W WO 0229098 A3 WO0229098 A3 WO 0229098A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- outcome
- viral infections
- factors affecting
- genetic factors
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001292125A AU2001292125A1 (en) | 2000-10-05 | 2001-10-05 | Genetic factors affecting the outcome of viral infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0024442.6 | 2000-10-05 | ||
GB0024442A GB0024442D0 (en) | 2000-10-05 | 2000-10-05 | Genetic factors affecting the outcome of viral infections |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002029098A2 WO2002029098A2 (en) | 2002-04-11 |
WO2002029098A3 true WO2002029098A3 (en) | 2003-10-16 |
Family
ID=9900751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/004472 WO2002029098A2 (en) | 2000-10-05 | 2001-10-05 | Genetic factors affecting the outcome of viral infections |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001292125A1 (en) |
GB (1) | GB0024442D0 (en) |
WO (1) | WO2002029098A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100481659B1 (en) * | 2001-10-16 | 2005-04-11 | 가부시끼가이샤 도시바 | Polymorphic Marker That Can Be Used to Assess the Efficacy of Interferon Therapy |
ATE493142T1 (en) * | 2003-11-05 | 2011-01-15 | Inst Rech Developpement Ird | IL-22 TO PREVENT INFECTIOUS DISEASES |
CN101361968B (en) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | Use of interleukin-22 in treating fatty liver |
RS57021B1 (en) * | 2007-11-07 | 2018-05-31 | Genentech Inc | Il-22 for use in treating microbial disorders |
WO2010149767A1 (en) | 2009-06-25 | 2010-12-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for determining the risk of occurence of liver fibrosis in an individual |
CN102260343A (en) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | Application of recombinant human G-CSF dimer for treating nerve damage disease |
CN102380091A (en) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | Application of interleukin-22 in curing virus hepatitis |
EP2737905B1 (en) | 2011-07-25 | 2019-09-11 | Generon (Shanghai) Corporation Ltd. | Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
CN103182072B (en) | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases |
EP2903634A1 (en) * | 2012-10-03 | 2015-08-12 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza |
JP6456356B2 (en) | 2013-03-15 | 2019-01-23 | ジェネンテック, インコーポレイテッド | IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
WO2019123398A1 (en) * | 2017-12-21 | 2019-06-27 | New Zealand Health Innovation Hub Management Limited | Method of analysis of mutations in the hepatitis b virus and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013875A1 (en) * | 1995-10-13 | 1997-04-17 | Imperial College Of Science, Technology & Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
WO2000008215A1 (en) * | 1998-08-07 | 2000-02-17 | Imperial College Of Science, Technology And Medicine | Predicting the outcome of virus infections |
WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
-
2000
- 2000-10-05 GB GB0024442A patent/GB0024442D0/en not_active Ceased
-
2001
- 2001-10-05 WO PCT/GB2001/004472 patent/WO2002029098A2/en active Application Filing
- 2001-10-05 AU AU2001292125A patent/AU2001292125A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013875A1 (en) * | 1995-10-13 | 1997-04-17 | Imperial College Of Science, Technology & Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
WO2000008215A1 (en) * | 1998-08-07 | 2000-02-17 | Imperial College Of Science, Technology And Medicine | Predicting the outcome of virus infections |
WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
Non-Patent Citations (7)
Title |
---|
HÖHLER T ET AL: "A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY. ENGLAND MAR 1998, vol. 111, no. 3, March 1998 (1998-03-01), pages 579 - 582, XP002235140, ISSN: 0009-9104 * |
HÖHLER T ET AL: "Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection.", JOURNAL OF MEDICAL VIROLOGY. UNITED STATES MAR 1998, vol. 54, no. 3, March 1998 (1998-03-01), pages 173 - 177, XP009007671, ISSN: 0146-6615 * |
KOTENKO S V ET AL: "IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A SECOND CHAIN OF THE INTERLEUKIN-10 RECEPTOR COMPLEX", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 19, 1997, pages 5894 - 5903, XP002046438, ISSN: 0261-4189 * |
KOTENKO SERGEI V ET AL: "Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2725 - 2732, XP002186669, ISSN: 0021-9258 * |
LEGARE R D ET AL: "CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.", LEUKEMIA (BASINGSTOKE), vol. 11, no. 12, December 1997 (1997-12-01), pages 2111 - 2119, XP009007556, ISSN: 0887-6924 * |
SPENCER SUSAN D ET AL: "The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 4, 16 February 1998 (1998-02-16), pages 571 - 578, XP002235139, ISSN: 0022-1007 * |
THURSZ M ET AL: "Influence of MHC class II genotype on outcome of infection with hepatitis C virus", LANCET, XX, XX, vol. 354, no. 9196, 18 December 1999 (1999-12-18), pages 2119 - 2124, XP004263267, ISSN: 0140-6736 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002029098A2 (en) | 2002-04-11 |
GB0024442D0 (en) | 2000-11-22 |
AU2001292125A1 (en) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002029098A3 (en) | Genetic factors affecting the outcome of viral infections | |
WO2007127801A3 (en) | Hepatitis c virus infection biomarkers | |
WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
WO2001077091A3 (en) | Ns5b hcv polymerase inhibitors | |
WO2006033995A3 (en) | Thiazolidin-4-ones having anti-hepatitis b activity | |
DK1747023T3 (en) | Methods and compositions for reducing HCV virus genomes in a target cell | |
DE602005027747D1 (en) | GENSILENCING SUITABLE CONSERVED HBV AND HCV SEQUENCES | |
YU37502A (en) | Infectious clones | |
Boglione et al. | Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon | |
MXPA01010392A (en) | Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences. | |
Olinger et al. | Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences | |
AU2003216523A1 (en) | Treatment of pre-core hepatitis b virus mutant infections | |
MXPA03000061A (en) | Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof. | |
WO2007031867A3 (en) | A hepatitis c virus non-stru tural ns3/4a fusion gene | |
WO2000078990A3 (en) | Search method for resistance to anti-proteases of a strain of the hiv 2 virus from a biological sample taken from a patient | |
WO2006043100A3 (en) | Methods for genotyping hcv | |
WO2003045335A3 (en) | Stem cell screening and transplantation therapy for hiv infection | |
WO2003053332A3 (en) | Composition and method for treating viral infection | |
WO2003037265A3 (en) | Method of treating viral infections | |
López et al. | ‘Hbe minus’ mutants of hepatitis B virus. Molecular characterization and its relation to viral genotypes | |
WO2002004595A3 (en) | Production of chimeric human papillomavirus | |
Prabdial-Sing et al. | Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa | |
Ali et al. | IL28B rs12979860 Genotypes is not useful for predicting treatment response over Pakistani Hepatitis-C infected patients treated for Sofosbuvir based therapy | |
EP1616967A3 (en) | Primers for isothermal amplification and genotyping of Hepatitis C virus | |
WO2002028174A1 (en) | Methods of infection with hepatitis c virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |